Publication Name	World Journal of Gastroenterology
Manuscript ID	7044
Country	United States

Received	2013-11-02 14:21
Peer-Review Started	2013-11-02 20:14
To Make the First Decision	2013-11-13 14:18
Return for Revision	2013-11-14 13:25
Revised	2013-12-02 01:12
Second Decision	2014-01-05 15:07
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-01-05 15:09
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-04-24 15:47
Publish the Manuscript Online	2014-05-18 12:31

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: A case report and literature review
Manuscript Source	Invited Manuscript
All Author List	Ruwaida Ben Musa, Lydia Usha, John Hibbeln and Ece A Mutlu
Funding Agency and Grant Number
Corresponding Author	Ece A Mutlu, MD, MS, MBA, Associate Professor of Medicine, IBD Program Director, Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Rush University, Rush Medical College, 1725 W, Harrison, Suite 206, Chicago, IL 60612, United States. ece_mutlu@rush.edu
Key Words	Tumor necrosis factor inhibitor; Ulcerative colitis; Breast Cancer; Inflammatory Bowel Disease; Adalimumab
Core Tip	Tumor necrosis factor (TNF)-α inhibitors are widely-used and effective treatments for many autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. However, it is believed that TNF-α inhibitors may also place patients at increased risk of cancer occurrence or recurrence. Many studies report increased risk of cancer following exposure to TNF-α inhibitors, but little has been reported for patients with cancer, receiving anti-TNF-α treatment. This is the first case of metastatic breast cancer in long term remission for 3 years in a patient treated with TNF-α inhibitors for ulcerative colitis, suggesting that patients with metastatic cancer could be treated with this class of medications without worsening.
Publish Date	2014-05-18 12:31
Citation	Ben Musa R, Usha L, Hibbeln J, Mutlu EA. TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: A case report and literature review. World J Gastroenterol 2014; 20(19): 5912-5917
URL	http://www.wjgnet.com/1007-9327/full/v20/i19/5912.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i19.5912

Full Article (PDF)	WJG-20-5912.pdf
Full Article (Word)	WJG-20-5912.doc
Manuscript File	7044-Review.docx
Answering Reviewers	7044-Answering reviewers.pdf
Copyright License Agreement	7044-Copyright assignment.pdf
Peer-review Report	7044-Peer review(s).pdf
Scientific Editor Work List	7044-Scientific editor work list.doc